An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Clinical trial NCT02477826 · COMPLETED
Trial details
- NCT number
- NCT02477826
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-08-05
- Primary completion
- 2024-10-25
- Enrollment
- 2747
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.